With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1228779-96-1,3-Nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)benzenesulfonamide,as a common compound, the synthetic route is as follows.
In a 100-mL flask (flask I) 2-[(1H-Pyrrolo[2,3-b]pyridine-5-yl)oxy]-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl]methyl]piperazin-1-yl]benzoic acid sulfate salt (compound 2a) (assay: 14.88 mmol), Et3N (12 mL, 87.5 mmol) and dichloromethane (85 mL) were combined at 20-25C and stirred for complete dissolution. In a 250-mL three necked round bottom flask (flask II) equipped with magnetic stirrer, thermometer, 3-nitro-4-[[(tetrahydropyran-4-yl)methyl]amino]-benzenesulfonamide (4.60 g, 14.58 mmol), DMAP (7.12 g, 58.34 mmol), N,N-diisopropylcarbodiimide (6 mL, 38.5 mmol) and dichloromethane (106 mL) were combined and stirred for 15 minutes. The resulting acid solution (flask I) was slowly added to the suspension of the sulfonamide (flask II) within 1 hour and reaction mixture agitated at 35-40C until reaction completion. The reaction mixture was extracted with 10% aqueous acetic acid (2×57 mL), 5% aqueous NaHCO3 (57 mL) and 5% aqueous NaCl (57 mL). After phase separation the organic layer was evaporated. Yield: 55%
1228779-96-1, 1228779-96-1 3-Nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)benzenesulfonamide 57474953, aTetrahydropyrans compound, is more and more widely used in various fields.
Reference£º
Patent; ASSIA CHEMICAL INDUSTRIES LTD.; TEVA PHARMACEUTICALS USA, INC.; POTARINE JUHASZ, Zsuzsa; STRUBA, Szabolcs; NEMETHNE RACZ, Csilla; TOTH, Zoltan Gabor; SZILAGYI, Andrea; KERTI-FERENCZI, Renata; MOLNAR, Sandor Janos; PASZTOR-DEBRECZENI, Nora; HAJKO, Janos; (100 pag.)WO2017/156398; (2017); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics